The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The sequencing of therapies for R/R MCL: BTKis and novel agents
Craig Portell, MD, University of Virginia, Charlottesville, VA, discusses the sequencing of therapies for relapsed/refractory (R/R) mantle cell lymphoma (MCL). He emphasizes that treatment in this setting is dependent on prior BTK inhibitor (BTKi) exposure and notes the potential for utilizing novel agents such as CAR T-cell therapy and non-covalent BTK inhibitors. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Beigene, Janssen/Pharmacyclics, Kite, Morphopsis, TG Therapeutics, AbbVie, Merck, AstraZeneca. Research Funding: Abbvie, Merck, Acerta/AstraZeneca, Lilly/Loxo, BeiGene, SeaGen/Pfizer
